HCPLive Network

Admission for Syncope Increases Risk of Death, Cardio Events

WEDNESDAY, Dec. 12 (HealthDay News) -- Among patients without previous comorbidity admitted for syncope, there is a significant increased risk of all-cause mortality, stroke, and cardiovascular hospitalization, according to a study published online Dec. 12 in the Journal of the American College of Cardiology.

Martin Huth Ruwald, M.D., from Gentofte Hospital in Hellerup, Denmark, and colleagues used nationwide administrative registries to identify 37,017 patients with a first-time diagnosis of syncope and matched them in a 1:5 ratio with 185,085 control subjects. The median age was 47 years, and 47 percent were male.

The researchers found that in the syncope group there were 3,023 deaths (8.2 percent), yielding an event rate of 14.3 per 1,000 person-years (PY), compared with 14,251 deaths (7.1 percent) in the control population. There was a significantly increased risk of all-cause mortality (hazard ratio [HR], 1.06; 95 percent confidence interval, 1.02 to 1.10) in the syncope group. In addition, there were significantly increased rates of cardiovascular hospitalization events (26.5 per 1,000 PY; HR, 1.74); recurrent syncope events (45.1 per 1,000 PY); stroke events (6.8 per 1,000 PY; HR, 1.35); and pacemaker or implantable cardioverter-defibrillator events (4.2 per 1,000 PY; HR, 5.52).

"First admission for syncope in a population without previous comorbidity significantly predicts the risk of all-cause mortality, stroke, cardiovascular hospitalization, device implantation, and recurrent syncope," the authors write. "The study suggests that syncope in seemingly healthy persons may be a first symptom of a more severe underlying cardiovascular disease."

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Further Reading
A new experimental device may be able to use converted energy from a patient’s heart to generate enough electricity to fully power a pacemaker.
M. Amin Karami, PhD, discusses study results presented at AHA 2012 that demonstrated the technical feasibility of using a piezoelectric energy-harvesting device to power a pacemaker.
The majority of patients with implantable cardioverter-defibrillators (ICDs) would want ICD deactivation in at least one scenario describing deteriorating health outcomes common in patients approaching the end of life, according to a study published online Jan. 28 in JAMA Internal Medicine.
Middle-aged and older individuals in the United States who have experienced job losses are at higher risk of having a heart attack, particularly during the first year of unemployment, according to a study published online Nov. 19 in the Archives of Internal Medicine.
Survival is similar for patients who receive implantable cardioverter-defibrillators as part of a randomized clinical trial or in routine clinical practice for primary prevention, according to research published in the Jan. 2 issue of the Journal of the American Medical Association.
New guidelines urge timely management for patients with ST-segment elevation myocardial infarction, according to a scientific report co-published online Dec. 17 in Circulation and the Journal of the American College of Cardiology.
Distance achieved in the six-minute walk test may be a practical measure of functional capacity that guides selection of therapy for patients with heart failure, according to research published online April 9 in the Journal of the American College of Cardiology.
More Reading